The price of tirilizumab is 2,180 yuan/100mg. Tirilizumab is a PD-1 monoclonal antibody therapeutic drug used in the treatment of uroepithelial cancer, advanced non-small cell lung cancer, etc. It will be included in the scope of medical insurance in 2020, and the price will be maintained at around RMB 2180/100mg, but the specific needs to be determined by combining the local medical insurance policy and the level of hospitals, which will be subject to certain differences. Tirilizumab, as a targeted therapeutic drug, needs to be treated by intravenous administration, and acts precisely on tumor tissues to inhibit the replication and growth of cancer cells, so as to stabilize the patient’s condition; however, during the period of medication, patients may have a lower white blood cell count, a lower neutrophil count, hypothyroidism, etc., and need to be guided by a doctor to use the medication.